In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 4, 2004, Pages 416-422

  Canavesi, Monica ^a   Baldini, Novella ^b   Leonardi, Amedeo ^c   Sironi, Giorgio ^c   Bellosta, Stefano ^a   Bernini, Franco ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Recordati SpA   (Italy)

Author keywords

Atherosclerosis; Calcium antagonists; Cholesterol esterification; Macrophages; Metalloproteinases

Indexed keywords

CALCIUM ANTAGONIST; CHOLESTEROL; DIHYDROPYRIDINE DERIVATIVE; LERCANIDIPINE; MATRIX METALLOPROTEINASE; NITRENDIPINE;

ACETYLATION; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL ESTERIFICATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENANTIOMER; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL ESTERS; DIHYDROPYRIDINES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MACROPHAGES, PERITONEAL; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MONOCYTES; SPECIES SPECIFICITY;

EID: 4644285047     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000139448.56713.3d     Document Type: Article

References (27)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
2. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.
3. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17:1859-1867.
4. Bernini F, Scurati N, Bonfadini G, et al. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol. 1995;15:1352-1358.
5. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671-1678.
6. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest. 1981;68:1366-1369.
7. Jost S, Deckers J, Rafflenbeul W, et al. Features of the angiographic evaluation of the INTACT study. International Nifedipine Trial on Antiatherosclerotic Therapy. Cardiovasc Drugs Ther. 1990;4(Suppl 5):1037-1045.
8. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Muticenter Isradipine Diuretic Atherosclerosis Study (M1DAS): a randomized controlled trial. JAMA. 1996;276:785-791.
9. Bernini F, Canavesi M, Bernardini E, et al. Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies. Br J Pharmacol. 1997;122:1209-1215.
10. Bellosta S, Canavesi M, Favari E, et al. Lacidipine modulates the secretion of matrix metal loproteinase-9 by human macrophages. J Pharmacol Exp Ther. 2001;296:736-743.
11. Soma MR, Donetti E, Seregni R, et al. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Br J Pharmacol. 1996;118:215-219.
12. Zanchetti A, Bond G, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Circulation. 2002;106:2422-2427.
13. Herbette LG, Vecchiarelli M, Sartani A, et al. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press. 1998;2:10-17.
14. Soma MR, Natali M, Donetti E, et al. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol. 1998;125:1471-1476.
15. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods. 1983;65:55-63.
17. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1301-1307.
18. Basu SK, Goldstein JL, Anderson RGW, et al. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA. 1976;73:3178-3182.
19. Nagelkerke JF, Van Berkel TJ. Rapid transport of fatty acids from rat liver endothelial to parenchymal cells after uptake of cholesteryl ester-labeled acetylated LDL. Biochim Biophys Acta. 1986;875:593-598.
20. Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells: continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem. 1980;255:9344-9352.
21. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994;218:325-329.
22. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 1995;91:2125-2131.
23. ++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanism. II. Characterization of intracellular morphologic changes. Arteriosclerosis. 1988;8:57-67.
24. Suzuki S, Nishimaki-Mogami T, Tamehiro N, et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol. 2004;24:519-525.
25. Suckling K, Stange EF. Role of acyl-CoA:cholesterol acyl-transferase in cellular cholesterol metabolism. J Lipid Res. 1985;26:647-671.
26. Leonardi A, Poggesi E, Taddei C, et al. In vitro calcium antagonist activity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol. 1997;29:S10-S18.
27. Barchielli M, et al. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol. 1997;29:S1-S15.